PT -期刊文章盟Federica Agosta AU -西尔维亚Basaia盟Federica Facente AU -卡米拉Cividini盟Edoardo卢卡雷利AU - Elisa Canu盟Veronica Castelnovo AU -朱塞佩•马格纳尼非盟-弗朗西斯卡卡索盟Paola Caroppo AU -萨拉Prioni AU -克里斯蒂娜•维拉盟卢西奥Tremolizzo盟Ildebrando Appollonio AU - Vincenzo Silani AU -马西莫菲利皮主持TI - FTLD光谱的表征通过先进diffusion-weighted MRI指标:连接体的方法(赛0 - 6.003)- 10.1212 / WNL援助。0000000000203682 DP - 2023年4月25日TA -神经病首页学第六PG - 4015 - 100 IP - 17补充2 4099 - //www.ez-admanager.com/content/100/17_Supplement_2/4015.short 4100 - //www.ez-admanager.com/content/100/17_Supplement_2/4015.full所以Neurology2023 4月25日;100 AB -目的:探讨结构性改变大脑网络的患者在额颞叶的变性(FTLD)频谱使用的连接体分析先进diffusion-weighted MRI指标。背景:核磁共振——是一个有前途的工具来描述基于网络的退化在神经退行性疾病。神经突方向色散和密度成像(NODDI)显示在结构连通性变化提供新的见解。设计/方法:34 behavioral-variant额颞叶痴呆(bvFTD), 11个语义变体原发性进行性失语(svPPA), 11迟滞型(nfvPPA)患者和48名健康对照组接受multi-shell扩散磁共振成像。计算分数各向异性(FA)地图。胞内体积分数(ICVF)地图也使用NODDI估计,提供一个直接量化神经突的完整性。图分析和评估——全球和本地拓扑网络结构属性和地区结构连接。结果:总体而言,普遍存在的结构性变化观察bvFTD患者相对于健康对照组和svPPA病人FA-derived网络属性。nfvPPA病人还显示改变FA拓扑性质在全球水平与健康对照组相比。节点权重的总和(SN)感觉运动叶透露,nfvPPA病人比svPPA显示连接强度的改变。 Moreover, nfvPPA patients showed a significant decreased FA in the left hemispheric fronto-temporal-insular regions relative to controls. Considering ICVF, more severe alterations compared to FA maps allowed to find differences also between svPPA and nfvPPA patients. ICVF graph analysis measures also showed that svPPA had a lower degree centrality and SN in the temporal lobe compared to controls.Conclusions: These findings suggest that conventional diffusion-tensor measures might be sensitive enough to highlight vulnerable connections in the FTLD spectrum. However, ICVF demonstrated to be a more specific biomarker to differentiate FTLD syndromes. Specifically, the benefits emerged in the differentiation between svPPA patients and other groups.Disclosure: Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC. Silvia Basaia has nothing to disclose. Dr. Facente has nothing to disclose. Ms. Cividini has nothing to disclose. Dr. Spinelli has nothing to disclose. The institution of Elisa Canu has received research support from Italian Ministry of Health . Dr. Castelnovo has nothing to disclose. Giuseppe Magnani has nothing to disclose. Dr. Caso has nothing to disclose. Paola Caroppo has nothing to disclose. Sara Prioni has nothing to disclose. Miss Villa has nothing to disclose. Lucio Tremolizzo has nothing to disclose. Dr. Appollonio has nothing to disclose. Dr. Silani has nothing to disclose. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries. Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).